JP2016540775A - 癌の処置のための化合物および方法 - Google Patents

癌の処置のための化合物および方法 Download PDF

Info

Publication number
JP2016540775A
JP2016540775A JP2016536733A JP2016536733A JP2016540775A JP 2016540775 A JP2016540775 A JP 2016540775A JP 2016536733 A JP2016536733 A JP 2016536733A JP 2016536733 A JP2016536733 A JP 2016536733A JP 2016540775 A JP2016540775 A JP 2016540775A
Authority
JP
Japan
Prior art keywords
crystalline form
cancer
hours
treatment
substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016536733A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016540775A5 (enExample
Inventor
ジョン シー． ジュニア アメディオ，
ジョン シー． ジュニア アメディオ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOLASIA PHARMA K.K.
Original Assignee
SOLASIA PHARMA K.K.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOLASIA PHARMA K.K. filed Critical SOLASIA PHARMA K.K.
Publication of JP2016540775A publication Critical patent/JP2016540775A/ja
Publication of JP2016540775A5 publication Critical patent/JP2016540775A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/72—Aliphatic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016536733A 2013-12-05 2014-12-05 癌の処置のための化合物および方法 Pending JP2016540775A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361912044P 2013-12-05 2013-12-05
US61/912,044 2013-12-05
PCT/US2014/068859 WO2015085208A1 (en) 2013-12-05 2014-12-05 Compounds and methods for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2016540775A true JP2016540775A (ja) 2016-12-28
JP2016540775A5 JP2016540775A5 (enExample) 2018-01-18

Family

ID=53274177

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016536733A Pending JP2016540775A (ja) 2013-12-05 2014-12-05 癌の処置のための化合物および方法

Country Status (6)

Country Link
US (1) US20160304546A1 (enExample)
JP (1) JP2016540775A (enExample)
KR (1) KR20160086960A (enExample)
CN (1) CN105899486A (enExample)
TW (1) TWI617305B (enExample)
WO (1) WO2015085208A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2019220961A1 (ja) * 2018-05-18 2020-05-28 ソレイジア・ファーマ株式会社 ダリナパルシンのアルカリ金属塩及び／又は無機酸付加塩の結晶型及びその製剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005527487A (ja) * 2002-01-07 2005-09-15 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 癌治療薬としての、ｓ−ジメチルアルシノ−チオコハク酸、ｓ−ジメチルアルシノ−２−チオ安息香酸、ｓ−（ジメチルアルシノ）グルタチオン
JP2009502971A (ja) * 2005-07-29 2009-01-29 ジオファーム オンコロジー， インコーポレイテッド がんを治療するための化合物および方法
JP2012051919A (ja) * 2004-07-16 2012-03-15 Texas A & M Univ System 癌の治療のための化合物および方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007082104A2 (en) * 2006-01-13 2007-07-19 The Texas A & M University System Compounds and methods for the treatment of cancer
TW200829261A (en) * 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
AU2008276451A1 (en) * 2007-07-17 2009-01-22 Zalicus Inc. Treatments of B-cell proliferative disorders
ES2901426T3 (es) * 2008-08-20 2022-03-22 Solasia Pharma K K Compuesto de organoarsénico para el tratamiento del cáncer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005527487A (ja) * 2002-01-07 2005-09-15 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 癌治療薬としての、ｓ−ジメチルアルシノ−チオコハク酸、ｓ−ジメチルアルシノ−２−チオ安息香酸、ｓ−（ジメチルアルシノ）グルタチオン
JP2012051919A (ja) * 2004-07-16 2012-03-15 Texas A & M Univ System 癌の治療のための化合物および方法
JP2009502971A (ja) * 2005-07-29 2009-01-29 ジオファーム オンコロジー， インコーポレイテッド がんを治療するための化合物および方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
平山令明編, 有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6011053065, 25 July 2008 (2008-07-25), pages 57 - 84, ISSN: 0003981107 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0003981108 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2019220961A1 (ja) * 2018-05-18 2020-05-28 ソレイジア・ファーマ株式会社 ダリナパルシンのアルカリ金属塩及び／又は無機酸付加塩の結晶型及びその製剤

Also Published As

Publication number Publication date
KR20160086960A (ko) 2016-07-20
CN105899486A (zh) 2016-08-24
TW201531292A (zh) 2015-08-16
US20160304546A1 (en) 2016-10-20
TWI617305B (zh) 2018-03-11
WO2015085208A1 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
US8865764B2 (en) Compounds and methods for the treatment of cancer
JP6315841B2 (ja) 有機ヒ素化合物および癌を処置するための方法
JP2016540775A (ja) 癌の処置のための化合物および方法
JP5202332B2 (ja) がんの治療のための化合物および方法
HK1228370A1 (en) Compounds and methods for the treatment of cancer
HK1117780B (en) Compounds and methods for the treatment of cancer
HK1164767B (en) Compounds and methods for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171204

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20180314

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180817

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190226